01 7Vyvanse
02 3Vyvanse/Elvanse
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2019 Revenue in Millions : 2,383
2018 Revenue in Millions : 0
Growth (%) : N/A
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2020 Revenue in Millions : 2,559
2019 Revenue in Millions : 2,431
Growth (%) : 5
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2020 Revenue in Millions : 2
2019 Revenue in Millions : 0
Growth (%) : New Launch in Japan
Main Therapeutic Indication : Neurology
Currency : USD
2021 Revenue in Millions : 2,652
2020 Revenue in Millions : 2,454
Growth (%) : 16
Main Therapeutic Indication : Neurology
Currency : USD
2021 Revenue in Millions : 5
2020 Revenue in Millions : 2
Growth (%) : 200
Main Therapeutic Indication : Neurology
Currency : USD
2022 Revenue in Millions : 3,220
2021 Revenue in Millions : 2,652
Growth (%) : 21
Main Therapeutic Indication : Neurology
Currency : USD
2022 Revenue in Millions : 10
2021 Revenue in Millions : 8
Growth (%) : 19
Main Therapeutic Indication : Neurology
Currency : USD
2023 Revenue in Millions : 2,978
2022 Revenue in Millions : 3,219
Growth (%) : 5
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2016 Revenue in Millions : 2,014
2015 Revenue in Millions : 1,722
Growth (%) : 17
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2017 Revenue in Millions : 2,161
2016 Revenue in Millions : 2,014
Growth (%) : 7
LOOKING FOR A SUPPLIER?